## PFE: Pfizer, Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 4.5% in lower entry zone (3.0-6.0%), top quartile (78th pct) cross-sectional ranking. Short-term MRS_5 (3.9%) confirms momentum alignment. Strong momentum (+6.3% 5-day acceleration). Outperforming sector by 3.0%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($25.27)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. Shorepoint Capital Partners LLC Invests $3.06 Million in Pfizer Inc. $PFE**
- Source: MarketBeat | 20251216T120904 | Somewhat-Bullish | Relevance: 100%
- Shorepoint Capital Partners LLC has initiated a new position in Pfizer Inc. (NYSE:PFE), acquiring 120,211 shares valued at approximately $3.06 million in the third quarter. Other institutional investors like Vanguard, Geode Capital Management, Norges Bank, Northern Trust Corp, and Amundi also significantly adjusted their holdings, bringing total institutional ownership to about 68.36%. Pfizer, with a market cap of around $150.4 billion, recently announced a quarterly dividend of $0.43 per share, yielding approximately 6.5%.

**2. Pfizer Stock (PFE) News, Forecasts, and Analyst Outlook: Whatâ€™s Driving Shares on December 15, 2025**
- Source: ts2.tech | 20251215T190839 | Neutral | Relevance: 100%
- Pfizer (NYSE: PFE) is under investor scrutiny on December 15, 2025, driven by a new collaboration with Adaptive Biotechnologies, a crucial 2026 guidance event set for December 16, and ongoing debates about its pipeline and value. The stock is trading around $26.36, near its 52-week high, with analysts maintaining a "Hold" stance and a significant 6.5% dividend yield attracting income-focused investors. The upcoming guidance call is expected to provide clarity on cost cuts, post-COVID revenue, and the integration of new obesity-focused deals.

**3. Pfizer Stock (PFE) News Today: Dividend, 2026 Guidance Call, Obesity Deals, and Analyst Forecasts (Dec. 15, 2025)**
- Source: ts2.tech | 20251215T130835 | Neutral | Relevance: 100%
- Pfizer (PFE) stock is trading around $25.85, ahead of its 2026 guidance call set for Dec. 16. The company recently declared a $0.43 quarterly dividend, announced a licensing agreement for an early-stage GLP-1 obesity candidate with YaoPharma, and continues to manage cost-cutting initiatives and pipeline momentum in oncology. Investors are closely watching for clarity on post-COVID growth, the impact of new acquisitions, and the company's strategy amid evolving regulatory landscapes, such as potential "black box" warnings for COVID-19 vaccines.

**4. 47,996 Shares in Pfizer Inc. $PFE Acquired by MASTERINVEST Kapitalanlage GmbH**
- Source: MarketBeat | 20251215T120848 | Neutral | Relevance: 100%
- MASTERINVEST Kapitalanlage GmbH recently acquired 47,996 shares of Pfizer Inc. ($PFE) in the second quarter, valued at approximately $1.163 million. This purchase is part of broader institutional investment activity in Pfizer, with other major investors like Vanguard Group Inc. and Geode Capital Management LLC also increasing their stakes. Analysts have issued a consensus "Hold" rating for Pfizer, with a target price of $28.33.

**5. Pfizer Declares First-Quarter 2026 Dividend**
- Source: BioSpace | 20251215T110826 | Bullish | Relevance: 100%
- Pfizer Inc. (NYSE: PFE) announced that its board of directors declared a $0.43 first-quarter 2026 dividend on the company's common stock. This dividend is payable on March 6, 2026, to shareholders of record as of January 23, 2026, marking the 349th consecutive quarterly dividend paid by Pfizer. The company highlighted its commitment to advancing healthcare through innovative medicines and vaccines, striving for quality, safety, and value.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | B of A Securiti | $28 | $29 | -3% |
| 2025-12-12 | Morgan Stanley | $28 | $32 | -12% |
| 2025-11-24 | Guggenheim | $35 | $33 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | B of A Securiti | main | Neutral |
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |
| 2025-11-24 | Guggenheim | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 11 ($0.22M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 31.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.4% (+0.2%)
- Blackrock Inc.: 8.8% (+0.5%)
- State Street Corpora: 5.3% (+0.9%)
- Geode Capital Manage: 2.3% (+1.2%)
- Morgan Stanley: 1.3% (+6.6%)

### Key Risks

1. Valuation stretched: PEG 14.2x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_10 improving +6.3% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 14.22 signals overvaluation risk, limited margin of safety. Quality metrics strong (margin 16%). Balance sheet: $4.0B free cash flow. Analyst sentiment negative (2 target cuts vs 1 raises). Institutional flow bullish (7 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $150.3B |
| Beta | 0.42 |
| 52W Range | $20.92 - $27.69 |
| Short Interest | 2.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 14.22 |
| Forward P/E | 8.7 |
| Current P/E | 8.4 |
| YoY Growth | -2.4% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -1.8% to 4.5% (+6.3% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 78th percentile. MRS_5 at 3.9% confirms short-term momentum alignment. Outperforming sector by 3.0pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 4.45% (CS: 78) | Strong |
| RSI_14 | 62.3 | Neutral |
| MACD Histogram | 0.06 | Bullish |
| vs SMA20 | 1.037x | Above |
| vs SMA50 | 1.052x | Above |
| vs SMA200 | 1.077x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $26.43
- **Stop Loss:** $25.27 (4.4% risk)
- **Target:** $28.17 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 1034
- **Position Value:** $27,328.62
- **Portfolio %:** 27.33%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-03 (Est: $0.60)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.63 | $0.87 | +37.4% |
| 2025Q2 | $0.57 | $0.78 | +35.9% |
| 2025Q1 | $0.67 | $0.92 | +36.5% |
| 2024Q4 | $0.46 | $0.63 | +37.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*